NKTX — Nkarta, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1787400 ·
Last close
$2.22
Market Cap
$159.01M
52W High
$3.72
52W Low
$1.70
ADV30
605,488
Next earnings
2026-11-10
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -43,128,000 | -40,368,000 | 337,645,000 | 24,958,000 | 89,907,000 |
| Mar 2026 | 0 | — | -30,876,000 | -27,832,000 | 372,073,000 | 27,356,000 | 86,213,000 |
| Dec 2025 | 0 | — | -30,961,000 | -27,409,000 | 404,209,000 | 39,634,000 | 91,884,000 |
| Sep 2025 | 0 | — | -27,286,000 | -21,715,000 | 427,236,000 | 60,114,000 | 89,336,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-87,286,000
Investing CF
$61,897,000
Financing CF
$147,000
CapEx
$-1,629,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.34
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-676,140,000
Inventory
—
Receivables
—
ST Investments
$203,072,000
EBIT TTM
$-116,309,000
Pretax Income TTM
$-99,933,000
Interest Exp TTM
—
Analysts
6
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -121,997,000 | -104,084,000 | 404,209,000 | 91,884,000 | 312,325,000 | -88,699,000 |
| Dec 2024 | 0 | -128,194,000 | -108,790,000 | 501,203,000 | 93,227,000 | 407,976,000 | -99,696,000 |
| Dec 2023 | 0 | -131,650,000 | -117,501,000 | 378,885,000 | 105,600,000 | 273,285,000 | -86,160,000 |
| Dec 2022 | 0 | -118,955,000 | -113,837,000 | 472,938,000 | 100,731,000 | 372,207,000 | -57,000,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-99,933,000
OpCashFlow TTM
—
Assets (Latest)
$372,073,000
Forward EPS
$-1.75
Max Pain — expiry 2026-11-20 (volume-derived — Yahoo OI feed degraded)
max pain strike: $2.50 · spot: $2.22 · call volume: 24 · put volume: 11
Expected Move to 2026-11-20:
±$0.81
(36.49%) —
implied range
$1.41 –
$3.03
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SCNX | Scienture Holdings, Inc. | $158.51M | $3.86 | — |
| NBP | NovaBridge Biosciences | $158.44M | $1.37 | — |
| MENS | Jyong Biotech Ltd. | $155.89M | $2.10 | — |
| CUE | Cue Biopharma, Inc. | $162.21M | $22.33 | — |
| MSLE | Satellos Bioscience Inc. | $155.83M | $7.34 | — |
News headlines (Yahoo Finance, 1h cache)
Nkarta to Participate in September Investor Conferences
2026-09-10 11:00 · Yahoo
Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026
2026-09-08 11:00 · Yahoo
Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights
2026-08-10 20:24 · Yahoo
Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
2026-06-26 12:45 · Yahoo
Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights
2026-05-12 20:01 · Yahoo
Here's Why We're Not Too Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Situation
2026-05-14 11:12 · Yahoo
Nkarta to Participate in Needham Virtual Healthcare Conference
2026-04-09 11:00 · Yahoo
Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers
2026-04-15 20:01 · Yahoo
Nkarta Targets ACR 2026 Data Reveal as Outpatient CAR NK Trials Advance
2026-09-27 19:02 · Yahoo
Cyllene Therapeutics Expands Leadership Team to Support Corporate Growth and Clinical Product Development
2026-07-23 05:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.